| Literature DB >> 27023176 |
N S Mehta-Raghavan1, S L Wert1, C Morley1, E N Graf1, E E Redei1.
Abstract
In this study, we sought to learn whether adverse events such as chronic restraint stress (CRS), or 'nurture' in the form of environmental enrichment (EE), could modify depression-like behavior and blood biomarker transcript levels in a genetic rat model of depression. The Wistar Kyoto More Immobile (WMI) is a genetic model of depression that aided in the identification of blood transcriptomic markers, which successfully distinguished adolescent and adult subjects with major depressive disorders from their matched no-disorder controls. Here, we followed the effects of CRS and EE in adult male WMIs and their genetically similar control strain, the Wistar Kyoto Less Immobile (WLI), that does not show depression-like behavior, by measuring the levels of these transcripts in the blood and hippocampus. In WLIs, increased depression-like behavior and transcriptomic changes were present in response to CRS, but in WMIs no behavioral or additive transcriptomic changes occurred. Environmental enrichment decreased both the inherent depression-like behavior in the WMIs and the behavioral difference between WMIs and WLIs, but did not reverse basal transcript level differences between the strains. The inverse behavioral change induced by CRS and EE in the WLIs did not result in parallel inverse expression changes of the transcriptomic markers, suggesting that these behavioral responses to the environment work via separate molecular pathways. In contrast, 'trait' transcriptomic markers with expression differences inherent and unchanging between the strains regardless of the environment suggest that in our model, environmental and genetic etiologies of depression work through independent molecular mechanisms.Entities:
Mesh:
Year: 2016 PMID: 27023176 PMCID: PMC4872452 DOI: 10.1038/tp.2016.28
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Blood transcript levels in WLIs and WMIs in response to CRS
| 13.13±0.24 | 13.44±0.51 | 14.10±0.28 | 12.56±0.38* | |
| 2.35±0.17 | 2.64±0.24 | 2.40±0.15 | 2.67±0.17 | |
| 7.72±0.10 | 7.23±0.37 | 7.04±0.14 | 7.40±0.53 | |
| 6.99±0.11 | 7.09±0.29 | 6.76±0.14 | 6.80±0.17 | |
| 8.35±0.25 | 8.26±0.38 | 9.42±0.35 | 8.74±0.39 | |
| 0.96±0.15 | 1.44±0.26 | 1.38±0.13 | 1.33±0.08 | |
| 5.22±0.16 | 4.50±0.25* | 4.90±0.20 | 4.58±0.12 | |
| 2.39±0.10 | 2.63±0.21 | 2.20±0.16 | 2.22±0.24 | |
| 5.00±0.12 | 4.50±0.17* | 4.45±0.16 | 4.59±0.09 | |
| 3.10±0.16 | 3.51±0.20 | 2.82±0.17 | 2.54±0.25 | |
| 3.01±0.18 | 3.11±0.19 | 2.86±0.07 | 3.15±0.17 | |
| 4.36±0.19 | 4.35±0.20 | 5.06±0.54 | 4.24±0.19 | |
| 3.66±0.05 | 3.72±0.10 | 3.66±0.21 | 3.29±0.19 | |
| 6.33±0.10 | 6.41±0.15 | 6.31±0.06 | 5.71±0.11** | |
| 5.20±0.10 | 4.67±0.10++ | 5.17±0.14 | 5.44±0.32 | |
Abbreviations: CRS, chronic restraint stress; WLI, Wistar Kyoto Less Immobile; WMI, Wistar Kyoto More Immobile.
Please note that the ΔCt values relate to relative concentration by 2−ΔCT.
*P<0.05, **P<0.01 by Bonferroni post hoc after significant two-way analysis of variance (strain × environment). Comparisons are within strain and between control and CRS.
++P<0.01 by Student's t-test. Comparisons are within strain and between control and CRS.
Figure 1Chronic restraint stress increases immobility behavior only in WLIs while environmental enrichment reduces immobility behavior in both strains. The presence or absence of immobility behavior (floating) was registered every 5 s (bins) in the second day of the FST (a) immediately following the chronic restraint stress procedure. (b) immediately after the environmental enrichment. Data are presented as mean±s.e.m. **P<0.01 Bonferonni adjusted post hoc, +P<0.05 Student's t-test. CRS, chronic restraint stress; FST, forced-swim test; WLI, Wistar Kyoto Less Immobile; WMI, Wistar Kyoto More Immobile.
Blood transcript levels in WLI and WMIs in response to EE
| 11.43±0.05 | 11.52±0.08 | 11.68±0.05 | 11.54±0.11 | |
| 4.38±0.12 | 5.72±0.23** | 4.21±0.22 | 4.93±0.24 | |
| 7.39±0.10 | 7.21±0.07 | 7.33±0.07 | 7.25±0.05 | |
| 5.93±0.08 | 5.60±0.05* | 5.82±0.09 | 6.13±0.07* | |
| 6.31±0.07 | 6.84±0.41 | 6.60±0.09 | 6.72±0.18 | |
| 3.75±0.11 | 4.43±0.17** | 3.81±0.10 | 3.90±0.19 | |
| 7.65±0.10 | 7.75±0.20 | 7.45±0.05 | 7.15±0.30 | |
| 4.90±0.09 | 4.73±0.25 | 4.74±0.11 | 4.49±0.03 | |
| 6.78±0.08 | 6.84±0.15 | 7.02±0.08 | 6.95±0.06 | |
| 5.73±0.15 | 4.56±0.35** | 5.25±0.21 | 4.88±0.14 | |
| 4.83±0.12 | 5.22±0.18 | 4.93±0.16 | 4.77±0.10 | |
| 6.13±0.12 | 7.57±0.29** | 6.45±0.32 | 7.06±0.26 | |
| 5.48±0.09 | 5.23±0.18 | 5.54±0.09 | 5.23±0.27 | |
| 10.00±0.09 | 9.47±0.14* | 10.05±0.16 | 9.45±0.16* | |
| 6.81±0.11 | 6.93±0.11 | 7.23±0.31 | 6.24±0.34* | |
Abbreviations: EE, environmental enrichment; WLI, Wistar Kyoto Less Immobile; WMI, Wistar Kyoto More Immobile.
Please note that the ΔCt values relate to relative concentration by 2−ΔCT.
*P<0.05, **P<0.01 by Bonferroni post hoc after significant two-way analysis of variance (strain × environment). Comparisons are within strain and between control and EE.
Hippocampal transcript levels in WLIs and WMIs in response to CRS
| 7.54±0.11 | 7.32±0.07 | 7.29±0.05 | 7.47±0.11 | |
| 5.37±0.12 | 4.71±0.16++ | 6.00±0.41 | 4.78±0.26** | |
| 6.82±0.11 | 7.51± 0.09* | 6.98±0.10 | 8.40±0.27** | |
| 3.93±0.04 | 3.98±0.11 | 4.32±0.11 | 3.69±0.15** | |
| 5.90±0.40 | 5.55±0.25 | 8.02±0.32 | 8.53±0.43 | |
| 6.95±0.29 | 7.75±0.33 | 8.64±0.32 | 8.08± 0.36 | |
| 5.78±0.10 | 5.39±0.16* | 5.93±0.08 | 6.02±0.11 | |
| 11.21±0.12 | 11.33±0.25 | 11.66±0.23 | 11.73±0.17 | |
| 12.87±0.44 | 14.06±0.29 | 12.68±0.28 | 13.68±0.34+ | |
| 4.26±0.11 | 5.05±0.45 | 5.45±0.45 | 7.04±0.38* | |
| 7.99±0.03 | 7.61±0.15+ | 8.19±0.08 | 7.66±0.34 | |
| 5.31±0.09 | 6.02±0.19* | 5.85±0.09 | 4.95±0.27** | |
| 6.05±0.10 | 5.78±0.11 | 6.20± 0.08 | 6.31±0.20 | |
| 7.50±0.17 | 6.61±0.14* | 9.37±0.19 | 8.65±0.38* | |
| 9.97±0.17 | 10.15±0.47 | 10.34±0.41 | 10.39±0.43 | |
Abbreviations: CRS, chronic restraint stress; WLI, Wistar Kyoto Less Immobile; WMI, Wistar Kyoto More Immobile.
Please note that the ΔCt values relate to relative concentration by 2−ΔCT.
*P<0.05, **P<0.01 by Bonferroni post hoc after significant two-way analysis of variance (strain × environment). Comparisons are within strain and between control and CRS.
+P<0.05, ++P<0.01 by Student's t-test. Comparisons are within strain and between control and CRS.
Hippocampal transcript levels in WLIs and WMIs in response to EE
| 8.21±0.05 | 8.54±0.08** | 8.26±0.04 | 8.54±0.06** | |
| 3.13±0.06 | 3.18±0.07 | 3.27±0.05 | 3.27±0.09 | |
| 7.83±0.15 | 8.04±0.22 | 7.74±0.14 | 7.69±0.13 | |
| 5.39±0.08 | 5.44±0.10 | 5.49±0.06 | 5.41±0.08 | |
| 3.13±0.06 | 3.28±0.08 | 3.17±0.10 | 3.45±0.07* | |
| 9.50±0.20 | 8.83±0.24 | 9.25±0.11 | 8.82±0.19 | |
| 6.38±0.11 | 6.36±0.19 | 6.30±0.11 | 6.47±0.14 | |
| 7.25±0.09 | 6.72±0.09** | 6.85±0.10 | 6.69±0.02 | |
| 10.63±0.12 | 10.50±0.18 | 10.07±0.14 | 10.29±0.17 | |
| 8.66±0.17 | 7.93±0.17* | 7.92±0.18 | 7.55±0.17 | |
| 7.20±0.07 | 6.67±0.10** | 6.98±0.07 | 6.64±0.09** | |
| 4.76±0.06 | 4.90±0.08 | 5.02±0.04 | 4.92±0.13 | |
| 7.49±0.12 | 7.13±0.10+ | 7.34±0.11 | 7.05±0.11 | |
| 5.48±0.06 | 5.00±0.08** | 5.34±0.10 | 5.24±0.10 | |
| 9.63±0.14 | 10.44±0.17* | 9.97±0.22 | 10.05±0.17 | |
Abbreviations: EE, environmental enrichment; WLI, Wistar Kyoto Less Immobile; WMI, Wistar Kyoto More Immobile.
Please note that the ΔCt values relate to relative concentration by 2−ΔCT.
*P<0.05, **P<0.01 by Bonferroni post hoc after significant two-way analysis of variance (strain × environment). Comparisons are within strain and between control and EE.
+P<0.05 by Student's t-test. Comparisons are within strain and between control and EE.
Figure 2Network analysis of blood transcripts. Interacting networks generated using Ingenuity Pathway Analysis were enriched for functions: gene expression, cell-to-cell signaling and interaction, hematological system development and function. The right-tailed Fisher's exact test of this network is 21, equivalent to P=7.58e−10. Inset legend shows symbol designations. ADRB2, beta-2 adrenergic receptor; APP, amyloid precursor protein; IRF3, interferon regulatory factor 3; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa B.